Kestra Q3 revenue $15.1M (+82% YoY); FY2025 guided $58-58.5M

KESTRA MEDICAL TECHNOLOGIES, LTD.

Revenue $15.1M in Q3 FY2025, up 82% YoY; gross margin improved to 43.4% from 10.6%.
GAAP net loss $21.8M vs $21.6M prior year; adjusted EBITDA loss $16.3M vs $16.2M.
Completed IPO in March 2025, raising net proceeds of $205.2M.
In-network covered lives for ASSURE system now exceed 285M; appointed Al Ford as CCO.
FY2025 revenue outlook $58M to $58.5M, representing 109%-110% growth vs FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.